ArazMarachelianMD

Pediatric Hematology & Oncology • Los Angeles, CA

Assistant Professor, Pediatrics, USC School of Medicine

Join to view full profile

Dr. Marachelian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Marachelian's full profile

Already have an account?

Office
4650 W Sunset Blvd
Los Angeles, CA 90027
Phone+1 323-361-2121

Fax+1 323-361-7128

Education & Training

Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 2003 - 2006
Children's Hospital Los AngelesResidency, Pediatrics, 2000 - 2003
University of California, Irvine, School of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2002 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

N99-02: Melphalan and Buthionine Sulfoximine Start of enrollment: 2001 Aug 01
Completed
Phase 1
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma Start of enrollment: 2010 Dec 01
Completed
Phase 1
Expanded Access Protocol Using 131I-MIBG
Available
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma Start of enrollment: 2012 Aug 01
Completed
Phase 1, Phase 2
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
Completed
Phase 2
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 1
MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12
Active, not recruiting
Phase 1
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Start of enrollment: 2020 Jun 11
Active, not recruiting
Phase 1
Neuroblastoma Biology Study Start of enrollment: 2011 Jul 01
Recruiting
Roles: Contact
Rapid Administration Pilot for Infusing Dinutuximab Start of enrollment: 2022 Oct 24
Recruiting
Phase 4
Roles: Contact, Principal Investigator
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Start of enrollment: 2024 Jul 01
Not yet recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

3 citations
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study.
Erica C Kaye, Jesse Smith, Yiwang Zhou, Rochelle Bagatell, Justin N Baker
Cancer. 2024-04-01
2 citations
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Michael D Hogarty, David S Ziegler, Andrea Franson, Yueh-Yun Chi, Denice Tsao-Wei
British Journal of Cancer. 2024-03-01
1 citations
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response toI-MIBG in patients with relapsed/refractory neuroblastoma.
Vandana Batra, Ajami Gikandi, Bruce Pawel, Daniel Martinez, M Meaghan Granger
Pediatric Blood & Cancer. 2024-01-01

Lectures

A phase I NANT study of lenalidomide with ch14.18 and isotretinoin (RA) in patients with refractory/recurrent neuroblastoma (RR-NB).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Children's Hospital Los Angeles Part of Clinical Trials for Neuroblastoma Radiation TherapyJuly 15th, 2022
Children’s Hospital Los Angeles Offers MIBG Therapy for NeuroblastomaJuly 14th, 2022
Ellis Injury Law Firm Proud to Donate to Create a Smile CharityNovember 4th, 2020
Join now to see all

ArazMarachelianMD

Dr. Marachelian is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.